Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 12, 2022 09:00 ET | Source: CohBar, Inc.

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
June 07, 2022 09:00 ET | Source: CohBar, Inc.

CohBar to Participate at Upcoming Conferences in June 2022

MENLO PARK, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
May 19, 2022 16:02 ET | Source: CohBar, Inc.

CohBar to Present at the H.C. Wainwright Global Investment Conference

MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
May 16, 2022 16:01 ET | Source: CohBar, Inc.

CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

MENLO PARK, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
May 12, 2022 09:00 ET | Source: CohBar, Inc.

CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal

MENLO PARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides...
May 02, 2022 09:00 ET | Source: CohBar, Inc.

CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022

MENLO PARK, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
March 29, 2022 16:01 ET | Source: CohBar, Inc.

CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

MENLO PARK, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
March 15, 2022 09:00 ET | Source: CohBar, Inc.

CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022

MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
January 03, 2022 09:00 ET | Source: CohBar, Inc.

CohBar to Present at H.C. Wainwright BIOCONNECT Conference

MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its...
December 17, 2021 09:00 ET | Source: CohBar, Inc.

CohBar Announces Changes to its Board of Directors and R&D Leadership

Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE...